Marker Therapeutics (MRKR) SEC Filings: History & Chart

Marker Therapeutics, Inc.(MRKR)

Biotechnology · Houston, TX

$1.01-0.05 (-4.72%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.

Houston, TX

5 employees

www.markertherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Juan F. Vera

View full financials

Form	Filing Date	Accepted	Document
10-Q	Aug 14, 2026	Aug 14, 2026	View filing
10-Q	May 15, 2026	May 15, 2026	View filing
8-K	May 4, 2026	May 4, 2026	View filing
DEFA14A	Mar 20, 2026	Mar 20, 2026	View filing
ARS	Mar 20, 2026	Mar 20, 2026	View filing
DEF 14A	Mar 20, 2026	Mar 20, 2026	View filing
8-K	Mar 19, 2026	Mar 18, 2026	View filing
10-K	Mar 18, 2026	Mar 18, 2026	View filing
PRE 14A	Mar 10, 2026	Mar 10, 2026	View filing
8-K	Feb 9, 2026	Feb 9, 2026	View filing
4	Nov 19, 2025	Nov 19, 2025	View filing
4	Nov 19, 2025	Nov 19, 2025	View filing
4	Nov 19, 2025	Nov 19, 2025	View filing
SC 13D/A	Nov 17, 2025	Nov 17, 2025	View filing
SC 13G/A	Nov 14, 2025	Nov 14, 2025	View filing
8-K	Nov 14, 2025	Nov 14, 2025	View filing
10-Q	Nov 13, 2025	Nov 13, 2025	View filing
8-K	Nov 5, 2025	Nov 5, 2025	View filing
4	Nov 4, 2025	Nov 4, 2025	View filing
4	Nov 4, 2025	Nov 4, 2025	View filing
3	Nov 4, 2025	Nov 4, 2025	View filing
8-K	Oct 6, 2025	Oct 6, 2025	View filing
8-K	Aug 26, 2025	Aug 26, 2025	View filing
SC 13D/A	Aug 20, 2025	Aug 20, 2025	View filing
SC 13D/A	Aug 19, 2025	Aug 19, 2025	View filing
SC 13D/A	Aug 18, 2025	Aug 18, 2025	View filing
10-Q	Aug 14, 2025	Aug 14, 2025	View filing
8-K	Aug 12, 2025	Aug 12, 2025	View filing
424B7	Aug 5, 2025	Aug 5, 2025	View filing
8-K	Jun 17, 2025	Jun 17, 2025	View filing

SEC Filings

Recent Filings